GOVX GeoVax Labs, Inc.

-

GeoVax Labs Beat Consensus Estimates

Monday, July 27, 2026 · 12:00 AM ET

GeoVax Labs (GOVX) reported a loss of $0.97 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $2.16 per share. The company beat consensus estimates by 55.09% while revenue fell 100.00% compared to the same quarter a year ago.

GeoVax Labs, Inc., is a development stage biotechnology company. It is engaged in developing human vaccines for diseases caused by Human Immunodeficiency Virus (HIV).

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.97)
Earnings Whisper®
Consensus Estimate
($2.16)
Earnings Surprise
Earnings Growth-177.1 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth-100.0 %